



## Tanzeum® (albiglutide) – Drug discontinuation

- On July 26, 2017, [GlaxoSmithKline \(GSK\) announced](#) the discontinuation of [Tanzeum \(albiglutide\)](#) injection due to limited prescribing of the medicine.
  - The discontinuation of Tanzeum is not due to any safety concerns.
  - Commercial supply of Tanzeum is expected to be depleted by July 2018.
- Tanzeum is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  - Tanzeum is not recommended as first-line therapy for patients inadequately controlled on diet and exercise.
  - Tanzeum has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
  - Tanzeum is not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
  - Tanzeum is not for patients with pre-existing severe gastrointestinal disease.
  - Tanzeum has not been studied in combination with prandial insulin.
- Tanzeum carries a boxed warning for the risk of thyroid C-cell tumors.
- Healthcare providers are advised to transition any existing patients taking Tanzeum to an alternative therapy as soon as possible and ensure that all patients are started on a different therapy by the end of June 2018 at the latest. No new patients should be started on Tanzeum therapy.
- Patients should speak to their doctor about which alternative treatment options may be right for them.
- For assistance or questions about the discontinuation of Tanzeum, contact the GSK Customer Response Center at **1-888-825-5249**.
- GSK has also provided a [consumer Q&A](#) to address any concerns regarding the Tanzeum discontinuation.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.